Drug intelligence / Profile preview

anemoside b4

Development stage
Preclinical
Lead developer
Guangxi Innovate Pharmaceutical
Modality
Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intraperitoneal
01

Overview

Anemoside B4 is a pentacyclic triterpenoid saponin isolated predominantly from the roots of *Pulsatilla chinensis*, a traditional Chinese medicinal herb. It exhibits potent anti-inflammatory and immunomodulatory activities, demonstrated in various preclinical studies. Mechanistically, Anemoside B4 inhibits the activation of multiple pro-inflammatory pathways, including the suppression of pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6) and reduction of neutrophil and white blood cell counts in models of infectious pneumonia. It acts via inhibition of the toll-like receptor 4 (TLR4)/MyD88 signaling pathway, directly interacts with and inhibits NEK7, thereby blocking NLRP3 inflammasome activation, and is also a direct inhibitor of pyruvate carboxylase, affecting cellular metabolic reprogramming and inflammation. Anemoside B4 is also able to inhibit E-selectin secretion and regulate additional inflammatory and immune pathways. It is being investigated as a therapeutic candidate for bacterial and viral pneumonia, acute gouty arthritis, inflammatory bowel disease/colitis, and other immunoinflammatory disorders[1][3][5][4][7][8][9].

Other names
anemoside b4pulchinenoside b4pulchinenoside cchinensioside apulsatilla saponin b4
02

Targets

MYD88 (Myeloid differentiation primary response protein MyD88)NEK7 (NIMA-related kinase 7)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κBPROC (Protein C)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on anemoside b4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anemoside b4.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call